BCV
CRSP icon

Banque Cantonale Vaudoise’s CRISPR Therapeutics CRSP Stock Holding History

Banque Cantonale Vaudoise’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$831K Sell
17,463
-227
-1% -$12K 0.03% 409
2025
Q4 		$928K Buy
17,690
+127
+0.7% +$7.61K 0.03% 373
2025
Q3 		$1.14M Sell
17,563
-747
-4% -$42.9K 0.04% 342
2025
Q2 		$891K Sell
18,310
-269
-1% -$10.4K 0.04% 371
2025
Q1 		$632K Buy
+18,579
New +$788K 0.03% 425
2024
Q3 		$804K Sell
17,111
-265
-2% -$13.4K 0.03% 346
2024
Q2 		$939K Buy
17,376
+782
+5% +$45.2K 0.04% 353
2024
Q1 		$1.13M Buy
16,594
+458
+3% +$32.8K 0.04% 334
2023
Q4 		$1.01M Sell
16,136
-72
-0.4% -$3.98K 0.04% 341
2023
Q3 		$736K Sell
16,208
-158
-1% -$8.16K 0.04% 385
2023
Q2 		$918K Buy
16,366
+692
+4% +$39.3K 0.04% 367
2023
Q1 		$709K Sell
15,674
-98
-0.6% -$4.76K 0.03% 375
2022
Q4 		$641K Buy
15,772
+133
+0.9% +$7.05K 0.03% 397
2022
Q3 		$1.02M Sell
15,639
-205
-1% -$14.9K 0.06% 322
2022
Q2 		$963K Buy
15,844
+11,615
+275% +$683K 0.05% 351
2022
Q1 		$266K Buy
4,229
+786
+23% +$49.4K 0.01% 721
2021
Q4 		$261K Sell
3,443
-623
-15% -$54.4K 0.01% 764
2021
Q3 		$455K Sell
4,066
-297
-7% -$37.3K 0.02% 586
2021
Q2 		$706K Sell
4,363
-360
-8% -$43.8K 0.03% 512
2021
Q1 		$575K Sell
4,723
-5,559
-54% -$839K 0.03% 500
2020
Q4 		$1.57M Buy
10,282
+1,310
+15% +$155K 0.09% 208
2020
Q3 		$751K Buy
8,972
+308
+4% +$27.3K 0.05% 331
2020
Q2 		$637K Buy
8,664
+833
+11% +$48.7K 0.05% 329
2020
Q1 		$332K Sell
7,831
-758
-9% -$39.1K 0.03% 480
2019
Q4 		$523K Buy
+8,589
New +$469K 0.04% 448

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GP
GSK plc London $599M AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Banque Cantonale Vaudoise's CRSP Position: Q1 2026 in Review

Banque Cantonale Vaudoise reduced its CRISPR Therapeutics (CRSP) stake by 1.3% in Q1 2026, selling an estimated $12K and leaving 17,463 shares worth $831K. The position accounts for 0.03% of the portfolio, ranked #409.

Banque Cantonale Vaudoise first reported a position in CRSP in Q4 2019 and has held it in 25 quarters since. The position peaked at $1.57M in Q4 2020. 488 funds tracked by Wall St. Rank hold CRSP as of Q1 2026.

  • Banque Cantonale Vaudoise held 17,463 shares of CRISPR Therapeutics worth $831K as of Q1 2026.
  • Banque Cantonale Vaudoise sold 227 CRISPR Therapeutics shares in Q1 2026, an estimated $12K.
  • CRISPR Therapeutics made up 0.03% of Banque Cantonale Vaudoise's portfolio in Q1 2026, its #409 holding.
  • Banque Cantonale Vaudoise first reported a position in CRISPR Therapeutics in Q4 2019 and has held it in 25 quarters since.
  • Banque Cantonale Vaudoise's CRISPR Therapeutics position peaked at $1.57M in Q4 2020.
  • 488 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2026.

Based on Banque Cantonale Vaudoise's 13F filing for Q1 2026, filed 20 Apr 2026.